MAPK13 promotes the progression of papillary thyroid cancer
European Thyroid Journal · 2025
DOI: 10.1530/etj-25-0083 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Runyu Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head and Neck Surgery, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study aims to analyze the genes that influence PTC progression and investigate the role of MAPK13 in PTC.
Methods
Differentially expressed genes (DEGs) in Gene Expression Omnibus (GEO): GSE3467, GSE3678, GSE33630, and GSE58545 were analyzed between PTC and normal thyroid tissues. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were performed on the DEGs using The Cancer Genome Atlas (TGCA) Program data. MAPK13 was subsequently identified as promoting progression in PTC. The association between MAPK13 expression and clinicopathological features was analyzed using data from public database and the collected cohort. The CCK-8 assay, EdU assay, wound healing assay, transwell assay, flow cytometry, GSEA enrichment analysis, and xenograft model were used to investigate the function of MAPK13 in PTC.
Results
Higher expression of MAPK13 was associated with poorer progression-free survival, higher tumor pathologic stage, extrathyroidal extension, lymph node metastasis, multifocal tumors, American Thyroid Association (ATA) stratification system level, and BRAF V600E mutation. Overexpression of MAPK13 significantly promoted cell proliferation, migration, and invasion, and inhibited apoptosis of PTC. Knockdown of MAPK13 significantly inhibited cell proliferation, migration, and invasion, and promoted apoptosis of PTC. Epithelial-mesenchymal transition (EMT) was significantly enriched in GSEA analysis. Higher MAPK13 expression was related to higher N-cadherin and lower E-cadherin expression. Knockdown of MAPK13 significantly prevented tumor growth in vivo .
Conclusion
MAPK13 promotes the malignant biological behavior of PTC cells and is associated with EMT. MAPK13 may be a potential biomarker for treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology Head and Neck Surgery, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
- Department of Otorhinolaryngology Head and Neck Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
- Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Department of Central Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
- Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
- School of Medicine, Shanghai University, Shanghai, China.
ORCID-Profile: Runyu Zhao, Yi Zhang, Shuixian Huang, Xiaoping Chen
Zitieren
APA
Zhao, R., Su, Z., Wan, Z., Qiao, P., Lu, Y., Chi, Y., Zheng, L., Zhang, Y., Huang, S., & Chen, X. (2025). MAPK13 promotes the progression of papillary thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-25-0083
Vancouver
Zhao R, Su Z, Wan Z, Qiao P, Lu Y, Chi Y, et al. MAPK13 promotes the progression of papillary thyroid cancer. European Thyroid Journal. 2025. doi:10.1530/etj-25-0083
BibTeX
@article{Zhao2025,
author = {Zhao, Runyu and Su, Ziqi and Wan, Zhihan and Qiao, Peipei and Lu, Yingying and Chi, Yongbin and Zheng, Liying and Zhang, Yi and Huang, Shuixian and Chen, Xiaoping},
title = {MAPK13 promotes the progression of papillary thyroid cancer},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-25-0083}
}
EUVIMED